SAN CARLOS, Calif. — LiquidCell Dx has appointed Mirna Jarosz as chief executive officer and Vincent A. Miller, M.D., as senior strategic advisor, adding experienced leadership as the company advances its blood-based tumor microenvironment profiling platform.
The precision diagnostics company said the hires strengthen its capabilities in operations, commercialization, and clinical strategy as it prepares for its next phase of growth.
LiquidCell Dx is developing a noninvasive platform designed to analyze the tumor microenvironment from blood samples, aiming to provide insights into how immune cells and surrounding biological factors influence cancer treatment response. While genomic profiling has enabled tumor analysis from blood, the broader tumor environment has remained difficult to assess in routine care.
Jarosz brings experience building genomics and diagnostics companies from early stages through commercialization. She was an early employee at Foundation Medicine, where she contributed to development of the FoundationOne genomic profiling assay, and at 10x Genomics, where she helped scale an early genomics platform. She has also held leadership roles at Ultima Genomics and Integrated DNA Technologies, serving as general manager of next-generation sequencing within Danaher’s life sciences platform.
“I have spent my career building genomics platforms from their earliest stages through commercial scale,” Jarosz said. “LiquidCell Dx has the science and the team to do that again, this time to bring an important layer of cancer biology into clinical use.”
As CEO, she will oversee company strategy, operations, and commercialization planning.
Miller previously served as the first chief medical officer at Foundation Medicine, where he helped establish comprehensive genomic profiling as a standard of care in oncology. He also spent more than two decades at Memorial Sloan-Kettering Cancer Center as an attending physician.
“As a practicing oncologist, I routinely saw patients with similar genomic profiles respond very differently to the same treatment,” Miller said. “The tumor microenvironment is a major reason why, and making it measurable from blood changes what clinicians can act on.”
In his advisory role, Miller will support clinical strategy, physician adoption, and the broader application of tumor microenvironment profiling.
The company’s co-founders include Aadel A. Chaudhuri, M.D., Ph.D., of Mayo Clinic and Aaron M. Newman, Ph.D., of Stanford University, who developed the underlying scientific and computational approach behind the platform. LiquidCell Dx said the expanded leadership team is intended to help translate complex cancer biology into clinical and commercial applications.
